ATE269103T1 - Stabilisierte wässerige glukagonlösungen enthaltend detergenzien - Google Patents

Stabilisierte wässerige glukagonlösungen enthaltend detergenzien

Info

Publication number: ATE269103T1
Authority: AT; Austria
Prior art keywords: solutions containing; stabilized aqueous; containing detergents; glucagon solutions; aqueous glucagon
Prior art date: 1998-03-13

Application number

AT99906095T

Other languages

English (en)

Inventor

Niels C Kaarsholm

Original Assignee

Novo Nordisk As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-03-13

Filing date

1999-03-08

Publication date

2004-07-15

1999-03-08 Application filed by Novo Nordisk As filed Critical Novo Nordisk As

1999-03-08 Priority claimed from PCT/DK1999/000115 external-priority patent/WO1999047160A1/en

2004-07-15 Application granted granted Critical

2004-07-15 Publication of ATE269103T1 publication Critical patent/ATE269103T1/de

Links

239000003599 detergent Substances 0.000 title abstract 3
102000051325 Glucagon Human genes 0.000 title abstract 2
108060003199 Glucagon Proteins 0.000 title abstract 2
MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 title abstract 2
229960004666 glucagon Drugs 0.000 title abstract 2
101710198884 GATA-type zinc finger protein 1 Proteins 0.000 abstract 1
DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 abstract 1
102100040918 Pro-glucagon Human genes 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
108090000765 processed proteins & peptides Proteins 0.000 abstract 1
230000003381 solubilizing effect Effects 0.000 abstract 1
230000000087 stabilizing effect Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Endocrinology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Obesity (AREA)
Oil, Petroleum & Natural Gas (AREA)
Hematology (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Emergency Medicine (AREA)
Child & Adolescent Psychology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Detergent Compositions (AREA)
Cosmetics (AREA)

AT99906095T 1998-03-13 1999-03-08 Stabilisierte wässerige glukagonlösungen enthaltend detergenzien ATE269103T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP98610006		1998-03-13
PCT/DK1999/000115 WO1999047160A1 (en)	1998-03-13	1999-03-08	Stabilized aqueous peptide solutions

Publications (1)

Publication Number	Publication Date
ATE269103T1 true ATE269103T1 (de)	2004-07-15

Family

ID=32524325

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT99906095T ATE269103T1 (de)	1998-03-13	1999-03-08	Stabilisierte wässerige glukagonlösungen enthaltend detergenzien

Country Status (3)

Country	Link
US (1)	US6384016B1 (de)
AT (1)	ATE269103T1 (de)
DE (1)	DE69918070T2 (de)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1999043708A1 (en) *	1998-02-27	1999-09-02	Novo Nordisk A/S	Glp-1 derivatives of glp-1 and exendin with protracted profile of action
US6528486B1 (en)	1999-07-12	2003-03-04	Zealand Pharma A/S	Peptide agonists of GLP-1 activity
HUP0204281A3 (en)	2000-01-27	2007-03-28	Lilly Co Eli	Process for sulubilizing glucagon-like peptide 1 (glp-1) compounds
US20020061838A1 (en) *	2000-05-17	2002-05-23	Barton Holmquist	Peptide pharmaceutical formulations
US20030119734A1 (en) *	2001-06-28	2003-06-26	Flink James M.	Stable formulation of modified GLP-1
ES2327328T3 (es)	2002-07-04	2009-10-28	Zealand Pharma A/S	Glp-1 y procedimientos para el tratamiento de la diabetes.
BR0314996A (pt)	2002-10-02	2005-08-09	Zealand Pharma As	Composição, composição farmaceuticamente aceitável, método para produzir a composição, métodos para estabilizar a exendina-4 (1-39) ou uma sua variante, derivado ou análogo contra a degradação, antes, durante ou após o uso pretendido, para tratar doenças, para tratar de estados de doenças associados com nìveis elevados de glicose do sangue, para a regulação dos nìveis de glicose do sangue, para a regulação do esvaziamento gástrico, para estimular a liberação de insulina em um mamìfero para reduzir o nìvel de glicose do sangue em um mamìfero, para reduzir o nìvel de lipìdeos plasmáticos em um mamìfero, para reduzir a mortalidade e a morbidez após o infarto miocárdico em um mamìfero, para estimular a liberação de insulina em um mamìfero, e para produzir uma exendina (1-39) estabilizada, e, exendina (1-39) estabilizada
WO2004105790A1 (en) *	2003-06-03	2004-12-09	Novo Nordisk A/S	Stabilized pharmaceutical peptide compositions
JP4936884B2 (ja) *	2003-06-03	2012-05-23	ノボ・ノルデイスク・エー／エス	安定化された薬学的ペプチド組成物
PT1687019T (pt) *	2003-11-20	2018-02-26	Novo Nordisk As	Formulações de péptidos que contêm polietileno glicol que são ótimas para produção e para utilização em dispositivos de injeção
EP1789434B1 (de) *	2004-08-31	2013-11-20	Novo Nordisk A/S	Verwendung von tris(hydroxymethyl)-aminomethan zur stabilisierung von peptiden, polypeptiden und proteinen
EP2494983B1 (de) *	2004-11-12	2019-04-24	Novo Nordisk A/S	Stabile formulierung von glp-1
JP2009500401A (ja) *	2005-07-07	2009-01-08	ポステックファンデーション	糖吸収調節剤及び薬学的組成物
PT3228320T (pt)	2008-10-17	2020-03-26	Sanofi Aventis Deutschland	Combinação de uma insulina e de um agonista do glp-1
KR101853606B1 (ko)	2009-07-06	2018-05-03	사노피-아벤티스 도이칠란트 게엠베하	메티오닌을 함유하는 수성 인슐린 제제
US9610329B2 (en) *	2009-10-22	2017-04-04	Albireo Pharma, Inc.	Stabilized glucagon solutions
US20110097386A1 (en) *	2009-10-22	2011-04-28	Biodel, Inc.	Stabilized glucagon solutions
DK2498802T3 (en)	2009-11-13	2015-04-13	Sanofi Aventis Deutschland	Pharmaceutical composition comprising a GLP-1 agonist, insulin and a methionine
KR101337322B1 (ko)	2009-11-13	2013-12-06	사노피-아벤티스 도이칠란트 게엠베하	Ｇｌｐ-1 효능제 및 메티오닌을 포함하는 약제학적 조성물
US9168288B2 (en)	2010-04-09	2015-10-27	Mount Sinai Hospital	Methods for treating disorders of the gastrointestinal tract using a GLP-1 agonist
CA2797133C (en)	2010-04-27	2019-08-06	Zealand Pharma A/S	Peptide conjugates of glp-1 receptor agonists and gastrin and their use
WO2011138802A1 (en) *	2010-05-07	2011-11-10	Sun Pharma Advanced Research Company Ltd.,	Injection solution
ES2606554T3 (es)	2010-08-30	2017-03-24	Sanofi-Aventis Deutschland Gmbh	Uso de AVE0010 para la fabricación de un medicamento para el tratamiento de la diabetes mellitus de tipo 2
US9821032B2 (en)	2011-05-13	2017-11-21	Sanofi-Aventis Deutschland Gmbh	Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
PL2750699T3 (pl)	2011-08-29	2015-12-31	Sanofi Aventis Deutschland	Kombinacja farmaceutyczna do stosowania w kontroli glikemii u pacjentów z cukrzycą typu 2
AR087744A1 (es)	2011-09-01	2014-04-16	Sanofi Aventis Deutschland	Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
TW201326194A (zh)	2011-11-03	2013-07-01	Zealand Pharma As	Ｇｌｐ－１胃泌素受體促效劑肽結合物
BR112014016889A8 (pt)	2012-01-09	2017-07-04	Adocia	composição sob a forma de uma solução aquosa injetável, sujo ph está compreendido entre 6,0 e 8,0 e, formulação de dose unitária com ph compreendido entre 7 e 7,8
MX356957B (es)	2012-07-23	2018-06-20	Zealand Pharma As	Analogos del glucagon.
US20150314003A2 (en)	2012-08-09	2015-11-05	Adocia	Injectable solution at ph 7 comprising at least one basal insulin the isoelectric point of which is between 5.8 and 8.5 and a hydrophobized anionic polymer
TWI608013B (zh)	2012-09-17	2017-12-11	西蘭製藥公司	升糖素類似物
TWI641381B (zh)	2013-02-04	2018-11-21	法商賽諾菲公司	胰島素類似物及／或胰島素衍生物之穩定化醫藥調配物
LT3057984T (lt)	2013-10-17	2018-12-27	Zealand Pharma A/S	Acilinti gliukagono analogai
US9988429B2 (en)	2013-10-17	2018-06-05	Zealand Pharma A/S	Glucagon analogues
AU2014345569B2 (en)	2013-11-06	2020-08-13	Zealand Pharma A/S	GIP-GLP-1 dual agonist compounds and methods
KR102310392B1 (ko)	2013-11-06	2021-10-13	질랜드 파마 에이/에스	글루카곤-ｇｌｐ-1-ｇｉｐ 삼원 효능제 화합물
CN112957455A (zh)	2014-01-09	2021-06-15	赛诺菲	胰岛素类似物和/或胰岛素衍生物的稳定化药物制剂
SG11201604706TA (en)	2014-01-09	2016-07-28	Sanofi Sa	Stabilized pharmaceutical formulations of insulin aspart
EP3091965A1 (de)	2014-01-09	2016-11-16	Sanofi	Stabilisierte glycerinfreie pharmazeutische formulierungen von insulinanaloga und/oder insulinderivaten
EP3189072B1 (de)	2014-09-05	2018-07-18	University of Copenhagen	Gip-peptidanalogen
RU2716985C2 (ru)	2014-10-29	2020-03-17	Зилэнд Фарма А/С	Соединения-агонисты gip и способы
AU2015359376B2 (en)	2014-12-12	2021-09-09	Sanofi-Aventis Deutschland Gmbh	Insulin glargine/lixisenatide fixed ratio formulation
JP6910950B2 (ja)	2015-01-12	2021-07-28	エンテリス・バイオファーマ・インコーポレイテッドＥｎｔｅｒｉｓＢｉｏｐｈａｒｍａ，Ｉｎｃ．	固形経口剤形
TN2017000349A1 (en)	2015-02-17	2019-01-16	Lilly Co Eli	Nasal powder formulation for treatment of hypoglycemia
TWI748945B (zh)	2015-03-13	2021-12-11	德商賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患治療
TW201705975A (zh)	2015-03-18	2017-02-16	賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患之治療
JP6989385B2 (ja)	2015-04-16	2022-01-05	ジーランドファーマアクティーゼルスカブ	アシル化グルカゴン類似体
AU2017277590A1 (en)	2016-06-07	2019-01-24	Adocia	Compositions in the form of an injectable aqueous solution, comprising human glucagon and an end-grafted copolyamino acid
SG10201911851VA (en)	2016-12-09	2020-02-27	Zealand Pharma As	Acylated glp-1/glp-2 dual agonists
WO2018220123A1 (en)	2017-05-31	2018-12-06	University Of Copenhagen	Long-acting gip peptide analogues
HUE066356T2 (hu)	2017-08-24	2024-07-28	Novo Nordisk As	GLP-1 készítmények és alkalmazásaik
EP3731858A1 (de)	2017-12-07	2020-11-04	Adocia	Zusammensetzungen in form einer injizierbaren wässrigen lösung mit menschlichem glucagon und einer copolyaminosäure
MX2020005915A (es)	2017-12-07	2020-10-19	Adocia	Composiciones en forma de una solución acuosa inyectable que comprende glucagón humano y un copoliaminoácido.
WO2019110838A1 (fr)	2017-12-07	2019-06-13	Adocia	Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacide
CA3084700A1 (en)	2017-12-07	2019-06-13	Adocia	Compositions in the form of an injectable aqueous solution comprising human glucagon and a copolyamino acid
FR3083087A1 (fr)	2018-06-29	2020-01-03	Adocia	Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacide
FR3067247A1 (fr)	2018-06-07	2018-12-14	Adocia	Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacide
MX2021006505A (es)	2018-12-03	2021-10-01	Antag Therapeutics Aps	Analogos peptidicos del peptido insulinotropico dependiente de glucosa (gip) modificados.
PE20221575A1 (es)	2020-02-18	2022-10-06	Novo Nordisk As	Formulaciones farmaceuticas

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1202607A (en) *	1968-01-10	1970-08-19	Novo Terapeutisk Labor As	Improvements in or relating to stable glucagon solutions and their preparation
US5120712A (en)	1986-05-05	1992-06-09	The General Hospital Corporation	Insulinotropic hormone
NZ250844A (en)	1993-04-07	1996-03-26	Pfizer	Treatment of non-insulin dependant diabetes with peptides; composition
US5652216A (en)	1994-05-26	1997-07-29	Novo Nordisk A/S	Pharmaceutical preparation
US5707641A (en) *	1994-10-13	1998-01-13	Pharmaderm Research & Development Ltd.	Formulations comprising therapeutically-active proteins or polypeptides

1999
- 1999-03-08 AT AT99906095T patent/ATE269103T1/de not_active IP Right Cessation
- 1999-03-08 US US09/265,141 patent/US6384016B1/en not_active Expired - Fee Related
- 1999-03-08 DE DE69918070T patent/DE69918070T2/de not_active Expired - Fee Related

Also Published As

Publication number	Publication date
DE69918070D1 (de)	2004-07-22
US6384016B1 (en)	2002-05-07
DE69918070T2 (de)	2005-08-25

Legal Events

Date	Code	Title	Description
2004-12-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE69918070D1 (de)	2004-07-22	Stabilisierte wässerige glukagonlösungen enthaltend detergenzien
RU97118224A (ru)	1999-07-27	Соединения и композиции для доставки активных агентов
LU91342I9 (de)	2018-12-31
MA22947A1 (fr)	1994-04-01	Compositions de blanchiment stabilisees.
DE69823320D1 (de)	2004-05-27	Entwicklernachfüllgerät
DK0948541T3 (da)	2006-07-17	Analoge af PTHrP
NO911861D0 (no)	1991-05-14	Stabilisert fgf-sammensetning.
ES2052488T3 (es)	1997-01-01	Peptidos antagonistas de la hormona de liberacion de la hormona luteinizante.
DE59911563D1 (de)	2005-03-10	Flüssige reinigungs- oder waschmittelzusammensetzung
ATE214698T1 (de)	2002-04-15	Neue carbamazepin hapten analoge
EP0607103A3 (de)	1997-07-09	Chelatbildende Gruppen enthaltende Somatostatinanaloge und deren radiomarkierten Zusammensetzungen.
BR9407124A (pt)	1996-09-10	Composições contendo surfactante
DE59402088D1 (de)	1997-04-17	Ultramilde tensidmischungen
AR023006A1 (es)	2002-09-04	Composicion de champu
DE60003943D1 (de)	2003-08-21	Trimegestone enthaltende pharmazeutische zusammensetzungen
DE69208492D1 (de)	1996-04-04	Stabilisierte Polyacetalzusammensetzungen
EP0616800A3 (de)	1995-02-15	Rieckstoffmittel mit verlängerter Diffusion.
NO913919L (no)	1992-04-06	Vandig, tiksotropisk vaskemiddelblanding.
EA199900962A1 (ru)	2000-08-28	Композиция солюбилизированного сертралина
MA24608A1 (fr)	1999-04-01	Compositions contenant un sensibilisant a l'insuline, un secretagogue d'insuline et un agent anti-heperglycemique inhibiteur d'alphat-glugosidase.
FR2684096B1 (fr)	1995-08-25	Compositions de ciments contenant des cendres volantes.
NL194506B (nl)	2002-02-01	Samenstelling, bevattende een elastomeer en een stabilisatormengsel.
TR199801460T2 (xx)	1998-10-21	Renk stabilize edici(ler) ve s�rfaktan(lar)� i�eren temizleyici bile�im.
ATE106438T1 (de)	1994-06-15	Benzotriazolderivate enthaltende schmiermittelzusammensetzungen.
GR3033334T3 (en)	2000-09-29	Stabilised hydroxylamine solutions